Techno-economic comparison of hydrogen- and electricity-driven technologies for the decarbonisation of domestic heating

Sustainable transition pathways currently being proposed for moving away from the use of natural gas and oil in domestic heating focus on two main energy vectors: electricity and hydrogen. The former transition would most likely be implemented using electric vapour-compression heat pumps, which are currently experiencing market growth in many industrialised countries. Electric heat pumps have proven to be an efficient alternative to gas boilers under certain conditions, but their techno-economic potential is highly dependent on the local climate conditions. Hydrogen-based heating systems, which could potentially utilise existing natural gas infrastructure, are being proposed as providing an attractive opportunity to maximise the use of existing assets to facilitate the energy-system transition. In this case, hydrogen can substitute natural gas in boilers or in thermally driven absorption heat pumps. Both heating system transition pathways may involve either installing new technologies at the household level or producing heat in centralised hubs and distributing it via district-heating systems. Although the potential of hydrogen in the context of heating decarbonisation has been explored in the past, a comprehensive comparison of electricity- and hydrogen-driven domestic heating options is lacking in literature. In this paper, a thermodynamic and economic methodology is developed to assess the competitiveness of a domestic-scale ammonia-water absorption heat pump driven by heat from a hydrogen boiler compared to a standalone hydrogen boiler, a classic vapour-compression heat pump and district heating, all from a homeowner’s perspective. Using a previously developed electric heat pump model, the different systems are compared for various climate conditions and fuel-price scenarios under a unified framework. The coefficient of performance of the absorption heat pump system under design conditions and the total system cost are found to be 1.4 and £5400, respectively. Comparing the annualised total costs of the options under consideration, it is shown that, assuming the future price of hydrogen for domestic end-users can be below 0.12 £/kWh, absorption heat pumps and hydrogen boilers can become competitive domestic heating technologies, and otherwise, electrification and the use of vapour-compression heat pump will be preferred

Operational optimisation of an air-source heat pump system with thermal energy storage for domestic applications

Electricity-driven air-source heat pumps are a promising element of the transition to lower-carbon energy systems. In this work, operational optimisation is performed of an air-source heat pump system aimed at providing space heating and domestic hot water to a single-family dwelling. The novelty of this work lies in the development of comprehensive thermal network models of two different system configurations: (i) a standard configuration of a heat pump system coupled to a hot-water cylinder; and (ii) an advanced configuration of a heat pump system coupled to two phase-change material thermal stores. Three different objective functions (operational cost, coefficient of performance, and self-sufficiency from a locally installed solar-PV system) are investigated and the proposed mixed-integer, non-linear optimisation problems are solved by employing a genetic algorithm. Simulations are conducted at two carefully selected European locations with different climate characteristics (Oban in Scotland, UK, and Munich in Southern Germany) over four seasons represented by typical weather weeks. Comparison of key results against a conventional operating strategy reveals that the use of smart operational strategies for the operation of the heat pump and thermal stores can lead to considerable economic savings for consumers and significant performance improvements over the system lifetime. Optimising the operation of the standard configuration leads to average annual cost savings of up to 22% and 20% at the UK and German locations, respectively. The optimisation of the advanced configuration with the two PCM stores shows even higher potential for economic savings – up to 39% and 29% per year at the respective locations – as this configuration allows for greater operational flexibility, and high-electricity-price periods can be almost completely avoided. Depending on the objective function, configuration and location, the system seasonal coefficient of performance varies between 2.4 and 2.8. Lastly, a significant (up to four-times) increase in the fraction of heat pump energy demand covered by an appropriately-sized rooftop PV system is demonstrated, increasing from 8% to 34% at the UK location and from 6% to 24% at the German location. The analysis highlights trade-offs between the objective functions, while the time-resolved results can be used to guide the future development of smart controllers for these applications

The influence of cadmium stress on the content of mineral nutrients and metal-binding proteins in arabidopsis halleri

We investigated the influence of cadmium stress on zinc hyperaccumulation, mineral nutrient uptake, and the content of metal-binding proteins in Arabidopsis halleri. The experiments were carried out using plants subjected to long-term cadmium exposure (40 days) in the concentrations of 45 and 225 μM Cd2+. Inductively coupled plasma-mass spectrometry, size exclusion chromatography coupled with plasma-mass spectrometry, and laser ablation inductively coupled plasma-mass spectrometry used for ablation of polyacylamide gels were employed to assess the content of investigated elements in plants as well as to identify metal-binding proteins. We found that A. halleri is able to translocate cadmium to the aerial parts in high amounts (translocation index >1). We showed that Zn content in plants decreased significantly with the increase of cadmium content in the growth medium. Different positive and negative correlations between Cd content and mineral nutrients were evidenced by our study. We identified more than ten low-molecular-weight (<100 kDa) Cd-binding proteins in Cd-treated plants. These proteins are unlikely to be phytochelatins or metallothioneins. We hypothesize that low-molecular-weight Cd-binding proteins can be involved in cadmium resistance in A. halleri

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

Background and purpose: Prospectively collected data comparing the safety and effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective was to directly compare the effectiveness and safety of NOACs in patients with newly diagnosed atrial fibrillation (AF). Methods: In GLORIA-AF, a large, prospective, global registry program, consecutive patients with newly diagnosed AF were followed for 3&nbsp;years. The comparative analyses for (1) dabigatran vs rivaroxaban or apixaban and (2) rivaroxaban vs apixaban were performed on propensity score (PS)-matched patient sets. Proportional hazards regression was used to estimate hazard ratios (HRs) for outcomes of interest. Results: The GLORIA-AF Phase III registry enrolled 21,300 patients between January 2014 and December 2016. Of these, 3839 were prescribed dabigatran, 4015 rivaroxaban and 4505 apixaban, with median ages of 71.0, 71.0, and 73.0&nbsp;years, respectively. In the PS-matched set, the adjusted HRs and 95% confidence intervals (CIs) for dabigatran vs rivaroxaban were, for stroke: 1.27 (0.79–2.03), major bleeding 0.59 (0.40–0.88), myocardial infarction 0.68 (0.40–1.16), and all-cause death 0.86 (0.67–1.10). For the comparison of dabigatran vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 1.16 (0.76–1.78), myocardial infarction 0.84 (0.48–1.46), major bleeding 0.98 (0.63–1.52) and all-cause death 1.01 (0.79–1.29). For the comparison of rivaroxaban vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 0.78 (0.52–1.19), myocardial infarction 0.96 (0.63–1.45), major bleeding 1.54 (1.14–2.08), and all-cause death 0.97 (0.80–1.19). Conclusions: Patients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death. Registration: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01468701, NCT01671007. Date of registration: September 2013

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation. the GLORIA-AF registry

Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores &gt;2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores &gt;2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score &gt;2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores &gt;2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores &gt;2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.